Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)

Summary

  • Tenofovir DF is approved for the treatment of compensated and decompensated chronic HBV infection in the United States and Europe (Table 3)[FDA TDF; EMA TDF]
    • It is also approved for the treatment of HIV infection.
  • Tenofovir DF has well-established safety and efficacy in treatment-naive patients with HBeAg-positive and HBeAg-negative disease and is associated with very low rates of resistance over longer-term use

    Action required